Ticagrelor Tablet, Film Coated
Product Images NDC 46708-500

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 46708-500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 10 (Ticagrelor 10figure)

A line chart comparing cumulative percentage of an event over 360 days from randomization for Ticagrelor 90 mg and Clopidogrel. The x-axis shows days from randomization, and the y-axis shows cumulative percentage. Ticagrelor's curve (solid line) lies below Clopidogrel's (dashed line), indicating a lower cumulative event rate. Data includes patient numbers at risk over time and hazard ratio statistics.*

FDA Label Image

Figure 11 (Ticagrelor 11figure)

A forest plot chart comparing the treatment effects of Ticagrelor versus Clopidogrel across various patient characteristics. The chart displays hazard ratios with 95% confidence intervals for overall treatment effect, geographic region, ASA dose, planned treatment approach, early PCI, CABG after randomization, diabetes history, prior TIA/stroke, glycoprotein inhibitor use, age group, sex, and race. The horizontal axis ranges from Ticagrelor better to Clopidogrel better.*

FDA Label Image

Figure 12 (Ticagrelor 12figure)

A table showing a comparison of Ticagrelor versus Clopidogrel by region (US and Non-US) with ASA dose categories in mg. It presents sample sizes (N), event counts (E), and hazard ratios (HR) with 95% confidence intervals (CI). A forest plot to the right illustrates HR with Ticagrelor favored left of center and Clopidogrel to the right.*

FDA Label Image

Figure 13 (Ticagrelor 13figure)

A Kaplan-Meier cumulative event percentage graph comparing Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo over approximately 1320 days from randomization. The graph shows patient risk numbers, hazard ratios, confidence intervals, and p-values for each group, illustrating time-to-event data between the treatments.*

FDA Label Image

Figure 14 (Ticagrelor 14figure)

A forest plot chart illustrating the hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus placebo across multiple patient characteristics, including age, sex, race, weight, BMI, geographic region, medical history, and other clinical factors, showing the overall treatment effect and subgroup analyses.*

FDA Label Image

Figure 15 (Ticagrelor 15figure)

A line graph depicting cumulative percentage events over months from randomization for Ticagrelor and Placebo groups. The solid line represents Ticagrelor and the dashed line represents Placebo, showing cumulative percentage on the y-axis versus months on the x-axis. The number of patients at risk decreases over time for both groups, presented in a table below the graph.*

FDA Label Image

Figure 16 (Ticagrelor 16figure)

Forest plot comparing the hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus placebo across various patient characteristics, including age, sex, race, body mass index, geographic region, baseline aspirin dose, HbA1c, eGFR, insulin use, history of angina, multivessel disease, history of PCI and CABG, smoking status, and duration of diabetes. The chart displays event rates and HRs, indicating relative performance of Ticagrelor against placebo.*

FDA Label Image

Figure 17 (Ticagrelor 17figur)

A cumulative percentage line graph comparing Ticagrelor 90 mg administered twice daily versus placebo over approximately 34 days post-randomization. The solid line represents Ticagrelor, and the dashed line represents placebo. The graph includes the number at risk for each group at several time points and shows cumulative event percentages with Ticagrelor lower than placebo throughout the period.*

FDA Label Image

Figure 18 (Ticagrelor 18figur)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals for various patient characteristics between Ticagrelor and placebo groups. It includes demographic factors like age, sex, race, weight, BMI, geographic region, diagnosis, and medical history, showing relative effectiveness outcomes with HR values plotted along a horizontal axis indicating whether Ticagrelor or placebo is favored.*

FDA Label Image

Figure 1 (Ticagrelor 1figure)

A line graph showing cumulative percentage over 360 days from first study drug dose for Ticagrelor 90 mg and Clopidogrel. The vertical axis represents cumulative percentage, and the horizontal axis represents days. The graph includes patient risk data for both drugs and a legend with the number of patients and events.*

FDA Label Image

Figure 2 (Ticagrelor 2figure)

A bar chart showing the percentage of patients who had an event following CABG surgery over days 1 to 8 or more. Two groups labeled T and C are compared across each day, with percentage values on the vertical axis and days on the horizontal axis. Numerical data below the chart correspond to patient counts in each group per day.*

FDA Label Image

Figure 3 (Ticagrelor 3figure)

A line graph showing the cumulative percentage of events over months from randomization for Ticagrelor and Placebo groups. The solid line represents Ticagrelor with 206 events out of 9,562 patients, and the dashed line represents Placebo with 100 events out of 9,531 patients. The x-axis shows months from 0 to 54, and the y-axis shows cumulative percentage from 0% to 7%. Patient numbers at risk at various time points are listed below the graph.*

FDA Label Image

Figure 4 (Ticagrelor 4figure)

A cumulative percentage line graph comparing Ticagrelor 90 mg twice daily with placebo over days from randomization. The solid line represents Ticagrelor 90 mg bd and the dashed line represents placebo, showing events and KM percentages. The x-axis shows days from randomization, and the y-axis displays cumulative percentage. Below the graph are numbers of patients at risk for each group across time points.*

FDA Label Image

Figure 5 (Ticagrelor 5figure)

A line graph showing Inhibition of Platelet Aggregation (IPA) percentage induced by 20 µM ADP over time (hours). The graph compares IPA for Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo, with Ticagrelor showing the highest IPA reaching near 90% within 1 hour, Clopidogrel showing moderate IPA around 50% at 8 hours, and Placebo showing minimal IPA around 10% at 8 hours.*

FDA Label Image

Figure 6 (Ticagrelor 6figure)

A line graph comparing IPA (%) induced by 20uM ADP over time for Ticagrelor, Clopidogrel, and Placebo. The main graph shows data over 10 days, and an inset graph shows data over 48 hours. Ticagrelor and Clopidogrel lines show a peak shortly after administration with Ticagrelor having higher IPA values, while Placebo remains near zero.*

FDA Label Image

Figure 7 (Ticagrelor 7figure)

A mean effect and 90% confidence interval (CI) chart comparing Ticagrelor and AR-C124910XX across intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and hepatic impairment. The chart shows change relative to reference values for pharmacokinetic parameters Cmax and AUC, with recommendations indicating no dose adjustment needed for any subgroup.*

FDA Label Image

Figure 8 (Ticagrelor 8fig)

A chart showing the mean effect and 90% confidence interval of Ticagrelor on drug interactions with various drugs. It displays the change relative to reference for peak concentration (Cmax) and area under the curve (AUC) for listed interacting drugs, along with corresponding recommendations such as avoiding concomitant use or dose adjustments.*

FDA Label Image

30 Tablets (Ticagrelor 90 mg)

Ticagrelor Tablets 90 mg film-coated tablets oral dosage form packaging label from Alembic Pharmaceuticals Limited. The label states 30 tablets per bottle, prescription only, with storage and warning instructions. The NDC number 46708-241-30 is visible.*

FDA Label Image

Figure 9 (Ticagrelor Figure 9)

A chart depicting the mean effect and 90% confidence interval of various interacting drugs when co-administered with Ticagrelor at different doses. It illustrates changes relative to the interacting drug alone, with data points for pharmacokinetics parameters Cmax, AUC, and PK. Recommendations include dose adjustments or no adjustment for drugs like simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine.*

FDA Label Image

Structure (Ticagrelor Structure)

Chemical structure of ticagrelor, showing its molecular components including a bicyclic core with fluorophenyl and other functional groups visible in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.